Press release: Bioglan and STADA partner to increase capacity to meet rising demand for Parkinson’s treatment
Bioglan and STADA partner to increase capacity to meet rising demand for Parkinson’s treatment
- Reig Jofre’s Bioglan subsidiary and STADA are investing EUR3 million to expand Bioglan’s facilities with a highly technological production line devoted to a patented combination therapy for Parkinson’s disease
- Bioglan is the exclusive manufacturer for the European market of the medicine, which is marketed by STADA as a treatment indicated for advanced Parkinson’s disease
- The therapy has already been approved in several European countries and is currently marketed by STADA in Nordic countries, Germany, Austria and Slovenia, with further launches imminent
Malmö and Bad Vilbel, 12 November 2021 – BIOGLAN, the Swedish subsidiary of the Spanish pharmaceutical company REIG JOFRE, (BME:RJF), and STADA Arzneimittel AG have signed an agreement to expand the production capacity for manufacturing a medicine used for the treatment of advanced Parkinson’s disease.
Since the launch of the pump-based combination medicine in 2020, Bioglan has already delivered around 250,000 doses via 100 batches, thereby meeting patient need in the initial launch countries. To meet the increasing demand for the therapy as STADA introduces it in further European countries over the coming months, the partners have agreed to build a new factory in Malmö, Sweden. Investment in this expansion that adds a sixth semi-solid production line at the site amounts to more than EUR3 million.
This line will manufacture a patented pharmaceutical gel formulation containing a combination of levodopa/carbidopa and entacapone in a 47ml pre-filled cartridge for continuous infusion into the small intestine through a discreet, lightweight and wearable pump that weighs 134 grams. The pump is currently prescribed for patients with late-stage Parkinson’s disease who are experiencing debilitating motor symptoms that can no longer be controlled by oral medication.
Following initial launches in Nordic countries, the therapy has already been approved in several European countries and is currently marketed by STADA in Germany, Austria and Slovenia, with launches in additional European and selected international markets scheduled in the near future.
Simon Björklund, CEO of Bioglan, commented: “This therapy is a new and highly interesting drug that show great progress with high patient demand. Continuous new launches in Europe require significant increased supply. I am glad to announce that the close and successful collaboration with STADA will enable this expansion. Bioglan anticipates over the long term manufacturing large volumes to a market that over time could run to hundreds of millions of euros.”
Robert Wood, managing director of STADA’s Britannia Pharmaceuticals subsidiary that specializes in central nervous system disorders such as Parkinson’s disease, said the facility expansion reflected the significant potential of this therapy to satisfy unmet patient need for this debilitating condition. “We believe this infusion formulation will have positive clinical benefits for patients who need a device-aided, continuous form of therapy which can resolve intractable motor fluctuations and improve their quality of life. We aim to broaden patient access to a device that is light, user-friendly, and discreet, enabling them to get on with their everyday lives.”
Bioglan belongs to the Spanish pharmaceutical company Reig Jofre and is the center of excellence for semi-solid product development and production. Bioglan offers both development and manufacturing services of pharmaceutical and medical devices. About 100 people work at Bioglan in the site in Malmö, Sweden. Reig Jofre focus its activity in research, development, manufacture and marketing of pharmaceutical products and food supplements. Reig Jofre is publicly traded on the Spanish Stock Exchange. For more information, www.bioglan.se.
About Reig Jofre
Founded in 1929 in Barcelona, Reig Jofre is a family-run pharmaceutical company, listed on the Spanish stock exchange's continuous market, dedicated to the research, development, manufacture and marketing of pharmaceutical products and food supplements at its four plants in Toledo (2), Barcelona and Malmö (Sweden). Reig Jofre organizes its product development activities into three business divisions: (1) Pharmaceutical Technologies specializing in sterile and lyophilized injectables and penicillin-derived antibiotics; (2) Speciality Pharmacare specializing in dermatology and osteoarticular disorders; and (3) Consumer Healthcare with consumer products under the Forté Pharma brand mostly in France, Belgium, Spain and Portugal, and other OTC areas. Reig Jofre has more than 1,100 employees, direct sales in 8 countries and more than 130 sales partners in more than 70 countries. The company closed 2020 with turnover of €230 million. Reig Jofre is listed under the code RJF. Share capital: 77,432,084 shares.
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2020, STADA achieved group sales of EUR 3,010.3 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 713.3 million. As of 31 December 2020, STADA employed 12,301 people worldwide.
REIG JOFRE information for journalists and investors:
Inma Santa-Pau - Director of Communication and Investor Relations firstname.lastname@example.org
Receive updated news about Reig Jofre by registering with the company’s subscription centre via our corporate website: www. reigjofre.com
STADA information for journalists:
STADA Arzneimittel AG - Media Relations Stadastrasse 2-18, 61118 Bad Vilbel, Germany
Phone: +49 (0) 6101 603-165 Fax: +49 (0) 6101 603-215 E-Mail: email@example.com
Or visit us on the Internet at www.stada.com/press Follow STADA Group on LinkedIn
STADA information for capital market participants:
STADA Arzneimittel AG - Investor & Creditor Relations Stadastrasse 2-18, 61118 Bad Vilbel, Germany Phone: +49 (0) 6101 603-4689 Fax: +49 (0) 6101 603-215 E-mail: firstname.lastname@example.org
Or visit us on the Internet at www.stada.com/investor-relations